RNA Sequencing Resolves Cryptic Pathogenic Variants in Mitochondrial Disease
Annals of Clinical and Translational Neurology · 2026-11 · 13 (11) · 2354-2370
DOI: 10.1002/acn3.70379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 25.04.2026. Verfasst von Zhimei Liu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Hauptthemen laut MEDLINE: Mitochondrial Diseases, Sequence Analysis, RNA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Education Commission, Ministry of Education, Republic of China (Taiwan).
Abstract (Originalsprache)
Objective
Mitochondrial diseases are the most common inherited metabolic disorders, characterized by pronounced clinical and genetic heterogeneity that complicates molecular diagnosis. Although DNA‐based sequencing approaches have become standard in genetic testing, up to half of patients remain without a definitive diagnosis. We aimed to perform RNA sequencing (RNA‐seq) of patient‐derived skin fibroblasts to enhance the molecular diagnostic efficacy of mitochondrial disease in undiagnosed cases in China.
Methods
We performed RNA‐seq on skin fibroblasts from 140 pediatric patients with suspected mitochondrial disease who remained genetically undiagnosed after whole exome sequencing (WES). Aberrant RNA expression and splicing were identified using the detection of RNA outliers pipeline (DROP). Based on WES findings, patients were stratified into a candidate group ( n = 28), in which RNA‐seq evaluated the pathogenicity of WES‐identified variants of uncertain significance and an unsolved group ( n = 112), in which RNA‐seq was used to pinpoint candidate genes. In six cases where RNA‐seq identified the aberrant RNA event but WES did not detect the causative variants, whole genome sequencing (WGS) was performed.
Results
Integrative RNA‐seq, WES, and WGS analysis resulted in a genetic diagnosis in 25% of patients overall (20/28 [71%] in the candidate group; 15/112 [13%] in the unsolved group). Aberrant splicing explained most candidate‐group diagnoses, including variants misclassified by in silico predictors such as SpliceAI. 14% of protein‐truncating variants predicted to undergo nonsense‐mediated decay (NMD) escaped degradation, highlighting the functional limits of current predictions. The variants identified in the unsolved cohort included synonymous, missense, deep intronic, near‐splice‐site variants, and large deletions. The most frequent among them was a recurrent synonymous East Asian founder mutation in ECHS1, accounting for seven cases. Interestingly, across 233 pathogenic variants associated with aberrant RNA phenotypes compiled from this study and prior reports, half were noncoding and half were coding variants.
Conclusion
RNA‐seq substantially enhances molecular diagnosis in mitochondrial disease by exposing cryptic splicing, regulatory, and NMD‐escape events invisible to DNA sequencing alone. These data advocate transcriptome analysis as an essential component of comprehensive genomic diagnostics in neurometabolic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Institute of Human Genetics, School of Medicine and Health, Technical University of Munich, Munich, Germany.
- Institute of Neurogenomics, Computational Health Center, Helmholtz Munich, Neuherberg, Germany.
- Cipher Gene Ltd, Beijing, China.
- Department of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Pediatrics, Weifang Maternal and Child Health Hospital, Weifang, China.
ORCID-Profile: Zhimei Liu, Manting Xu, Holger Prokisch, Fang Fang
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Education Commission
- Ministry of Education, Republic of China (Taiwan)
- Ministry of Education
Zitieren
APA
Liu, Z., Duan, X., Peymani, F., Wang, J., Bao, C., Xu, C., Zou, Y., Zhang, Z., Zhang, Y., Li, T., Pavlov, M., Wang, J., Song, M., Song, T., Han, X., Sun, M., Shen, D., Duan, R., Jiang, H., …, & Fang, F. (2026). RNA Sequencing Resolves Cryptic Pathogenic Variants in Mitochondrial Disease. Annals of Clinical and Translational Neurology, 13(11), 2354-2370. https://doi.org/10.1002/acn3.70379
Vancouver
Liu Z, Duan X, Peymani F, Wang J, Bao C, Xu C, et al. RNA Sequencing Resolves Cryptic Pathogenic Variants in Mitochondrial Disease. Annals of Clinical and Translational Neurology. 2026;13(11):2354-2370. doi:10.1002/acn3.70379
BibTeX
@article{Liu2026,
author = {Liu, Zhimei and Duan, Xin and Peymani, Fatemeh and Wang, Jia and Bao, Chengjia and Xu, Chaolong and Zou, Ying and Zhang, Zixuan and Zhang, Yunxi and Li, Tongyue and Pavlov, Martin and Wang, Junling and Song, Minhan and Song, Tianyu and Han, Xiaodi and Sun, Mingxi and Shen, Danmin and Duan, Ruoyu and Jiang, Huafang and Xu, Manting and Prokisch, Holger and Fang, Fang},
title = {RNA Sequencing Resolves Cryptic Pathogenic Variants in Mitochondrial Disease},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
volume = {13},
number = {11},
pages = {2354--2370},
doi = {10.1002/acn3.70379}
}
EUVIMED